Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11201864 | 0.82 | GAA (0.44) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1245810 | 0.81 | GAA (0.43) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4154250 | 0.81 | GAA (0.43) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4147861 | 0.81 | GAA (0.43) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11034132 | 0.81 | MAPT (0.35) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7451703 | 0.81 | SMN1; SMN2 (0.50) | LMNARAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL6980493 | 0.80 | MEN1 (0.53) | MAPTRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL6980498 | 0.80 | MEN1 (0.53) | MAPTRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL395325 | 0.80 | DHODH (0.46) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4837457 | 0.79 | SMN1; SMN2 (0.46) | MAPTLMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008093940-A1 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION PROCESS FOR THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 2008-08-07 | — | — | WO | disclosed |
| US-7009053-B2 | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same | Yungjin Pharmaceuticals Co., Ltd. (KR) | 2006-03-07 | — | — | US | disclosed |
| EP-1499593-A4 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUNGJIN PHARMACAUTICAL CO LTD (KR) | 2006-02-01 | — | — | EP | disclosed |
| EP-1499593-A1 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Yungjin Pharmacautical Co., Ltd. (KR) | 2005-01-26 | — | — | EP | disclosed |
| US-20040260094-A1 | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-12-23 | — | — | US | disclosed |
| WO-2003093240-A1 | QUINOLINE DERIVATIVES AS CASPASE-3 INHIBITOR, PREPARATION FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260094-A1 | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same | CASP1, CASP3, CASP2 | MAPT 3734/4885LMNA 108/4885RAB9A 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.